Bayer’s Summer Showdown: A $2.45 Billion Eye Bet and a Supreme Court Ruling That Could Reshape the Stock
Published on 06/23/2026 at 04:03 | Redaktion boerse-global.de
Bayer faces a defining fortnight. The $2.45 billion acquisition of Perfuse Therapeutics closed on June 17, locking in an experimental glaucoma implant that could one day ease the pressure from expiring blockbuster patents. Yet the stock remains pinned near €38 — waiting on a single Supreme Court decision that would either wipe out roughly 65,000 glyphosate lawsuits or prolong a nightmare.
The contrasting narratives are hard to reconcile. On one side, the Leverkusen-based group is investing aggressively in ophthalmology, betting that PER-001 — a sustained-release implant currently in Phase II that targets both glaucoma and diabetic retinopathy — can fill the revenue hole left by Eylea’s loss of exclusivity. On the other, the legal quagmire surrounding Roundup continues to drain cash and management attention, with the final hearing for the class-action settlement scheduled for July 9 in St. Louis.
A Pipeline Under a Microscope
Bayer paid $300 million upfront for Perfuse, with the remainder of the $2.45 billion total tied to development and commercial milestones. The asset, PER-001, is an endothelin receptor blocker delivered via intravitreal implant — a novel mechanism that has yet to gain approval in any eye indication. If successful, it would address two of the world’s most common causes of blindness, both considered chronically undertreated.
But Phase II compounds often falter in pivotal trials. The pressure on Bayer’s pharma division is rising: Xarelto’s patent cliff is already here, and Eylea’s exclusivity is fading. The group is counting on Nubeqa and Kerendia to deliver growth, but an immediate blockbuster from PER-001 is still years away. Asundexian, an oral anticoagulant currently under accelerated FDA review, could offer a nearer catalyst — a decision is expected in the second half of 2026.
Should investors sell immediately? Or is it worth buying Bayer?
Meanwhile, the contrast with a largely stable consumer health business is sharp. In June, Bayer opened a second innovation centre in China’s Shandong province, deepening its presence in what is already the division’s second-largest market. The centre will focus on skin and digestive health, using local consumer insights to feed global platforms.
The Supreme Court’s Pivot Point
All eyes are on the high court’s ruling in the “Durnell” case, expected by the end of June. At stake is a fundamental legal question: can a state impose penalties for a product that the US Environmental Protection Agency deems safe? A victory for Bayer would render tens of thousands of pending claims moot and hand the company a decisive political and legal shield.
UBS analyst Matthew Weston puts the odds of a favourable outcome at 70%. Even a partial win in the Missouri settlement process has given the company breathing room. Still, Barclays warns of timing risks around the July hearings, with jurisdictional questions still unresolved.
If the Supreme Court decides against Bayer, the debt load — €32.5 billion in net debt as of end-March — will reassert itself as the dominant theme. Legal costs already consumed €2 billion in the first quarter alone, crimping free cash flow and limiting strategic flexibility. The Singapore government cut its stake from 4.17% to 2.90%, and Goldman Sachs reduced its voting rights to 4.84% from 5.40% in just three days.
Mixed Signals from the Market
The stock trades at €38.01, marginally above its 200-day moving average of €36.28 and its 50-day average of €37.76. Berenberg raised its price target to €40.50 in June, but the shares have struggled to break meaningfully higher. Operationally, Bayer delivered €13.4 billion in currency-adjusted first-quarter revenue and an operating result of roughly €4.45 billion — solid figures that are overshadowed by legal uncertainty.
Bayer at a turning point? This analysis reveals what investors need to know now.
Adding another layer of geopolitical risk, the US Trade Representative is reviewing Germany’s drug pricing rules, raising the possibility of punitive tariffs on German medicines. Any escalation would hit Bayer’s pharma exports to its largest market.
Two binary catalysts now crowd the calendar: the Supreme Court ruling and the July 9 settlement hearing. If both break Bayer’s way, the stock could re-rate quickly as investors refocus on the pipeline and the underlying earnings power. If they go wrong, the debt and litigation vortex will tighten again. The market is not pricing in a middle ground.
Ad
Bayer Stock: New Analysis - 23 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
